Skip to content
PeptidePlotter logo PeptidePlotter
Search (no-JS fallback)

Peptides

Mazdutide

Also called Maz · GLP-1/GCG

Mazdutide is a weekly weight-management drug that also has a type 2 diabetes indication in China. People comparing it with tirzepatide want to know about appetite, weight loss and tolerability; it targets a different combination of hormone receptors, so doses are not interchangeable.

Open the plotter Sources

Dosage & duration

GLORY-1 study · Chinese adults with overweight or obesity

Published phase 3 treatment groups

Published example · product-specific
Dose
4 mg or 6 mg target dose
How often
Once weekly by subcutaneous injection
How long
48-week study; primary assessment at week 32

Target treatment groups, not starting doses or a self-directed titration. Study length is not a recommended cycle.

Sources: 1 · 2

More quick facts
Why people research it
Weight management
Sources : 1 · 2
Compared with tirzepatide
A different second target
Sources : 1 · 2
Main trade-off
Stomach-related side effects
Sources : 1 · 2

Weight-management questions

Weight loss, a different pathway and tolerability

  • Weight loss

    GLORY-1 found average weight loss in Chinese adults with overweight or obesity.

  • A different second target

    GLP-1 plus glucagon activity does not by itself establish an advantage over tirzepatide.

  • Stomach symptoms

    Gastrointestinal effects were the most frequently reported events in GLORY-1.

GLORY-1 compared mazdutide with placebo, not tirzepatide. Sources and context
In this guide

What makes mazdutide interesting?

The appeal is another effective weight-management option, including a different hormone target from tirzepatide. In GLORY-1, the 6 mg group lost about 14% of starting weight on average at 48 weeks versus a small gain with placebo. Individual results varied.

What are physique users looking for?

Community questions focus on losing fat without losing muscle, appetite control and whether switching from tirzepatide would feel different. Bodybuilding discussions also debate lean-mass findings, while individual experience reports range from enthusiasm to little noticeable effect.

Those reports do not establish better muscle retention or a more effective cut. GLORY-1 studied Chinese adults with overweight or obesity, with diet and exercise guidance; it did not test a muscle-preserving bodybuilding regimen. The receptor combination is a reason to study mazdutide, not proof that it is a better fit for a lifter.

Does it beat tirzepatide?

That trial compared mazdutide with placebo, not tirzepatide. Comparing headline percentages from different populations does not settle which works better for an individual, and the same weekly milligram amount is not an equivalent dose.

Approval and product matter

The cited filing confirms Chinese indications. It does not mean a research vial sold elsewhere is an approved medicine or the same formulation used in the trial. Regulatory status and access need checking in the country where treatment is considered.

Duration and tolerability

The trial followed treatment over months. Stomach-related effects were common, mostly mild to moderate in that study. The published duration should not be read as a cycle with an automatic stopping point.

Model details: Mazdutide · estimated

How to read this estimate

Estimated from label parameters; the calibration peak is calculated, not a reported measurement. Compare amounts and timing in mg.

Concentrations estimated from label parameters and an assumed absorption profile.

Assumptions, calculation and sources

Innovent mazdutide injection; label published on manufacturer domain.. subcutaneous. Chinese label population: adults with overweight/obesity; fixed mean PK parameters..

mazdutide: estimated concentration in plasma (ng/mL).

Innovent Chinese label: Tmax7–28h, rounded mean terminal half-life about10days. Label apparent clearance .0368L/h and volume11.2L.

Calibration dose
2 mg
Derived calibration peak
165.0307 ng/mL
Peak timing used
24 hours
Terminal half-life used
210.9578 hours
Reconstructed absorption rate
0.1669593 /hour
  • Both clearance and volume are apparent (CL/F, V/F); F is already included. Do not apply another F. Cmax=(doseMg*1000/(V/F))*exp(-ke*Tmax) ng/mL.
  • Dose scaling and repeated-dose superposition use fixed parameters; the example dose does not calibrate the curve.
  • A one-compartment structure and 24 h peak time are authored assumptions; the calculated peak is not an observed endpoint.
  • Apparent volume 11.2 L and clearance 0.0368 L/h imply a 210.96 h half-life; the label independently rounds half-life to about 10 days.
  • Proposed Cmax is CALCULATED, not an observed study endpoint. Prefer metadata saying label-parameter estimate over observed-endpoint estimate.
  • First-order absorption and one compartment are our structural assumptions; label does not supply ka or a complete published compartment model.
  • Label mean apparent volume/clearance imply an8.79-day half-life rather than rounded10days; these independently summarized quantities need not coincide.
  • Older trial first-dose Tmax~72h differs from current product label; formulation/cohort differences remain unresolved, so do not combine them silently.

Estimate mazdutide-source-estimate-2026-10 · version 1

Common questions

Can I substitute the same milligrams for tirzepatide?

No equivalent-dose conversion is established by these sources.

Is combining it with tirzepatide the same as retatrutide?

No. Combining two drugs does not reproduce the exposure or evidence of a different single molecule.

Sources Labels, studies and notes behind this guide

Catalog evidence: Human clinical trials. This describes the type of evidence, not a clinical review of every claim.

Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.

Notes on the quick facts

Why people research it
A phase 3 trial found meaningful average weight loss in Chinese adults.
Compared with tirzepatide
Mazdutide combines GLP-1 with glucagon activity; that alone does not prove superiority.
Main trade-off
Gastrointestinal effects were the most frequently reported events in GLORY-1.
Related compounds and examples

Related compounds

Survodutide

Survodutide for weight and liver fat: research doses, treatment duration and practical differences from other incretin drugs.

Semaglutide Injection (Ozempic/Wegovy)

Semaglutide can reduce hunger and food intake, helping people lose weight. Wegovy injections are prescribed for weight management; Ozempic injections treat type 2 diabetes. Both are taken weekly, with gradual dose increases to help manage digestive side effects.

Semaglutide Oral (Rybelsus)

Oral semaglutide offers a daily tablet option for adults with type 2 diabetes who want to avoid injections. The morning routine matters: food, drink and other tablets affect absorption, and different semaglutide products cannot be compared milligram for milligram.

Comments

Loading comments…